Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update (Q35771833)

10 August 2017

Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update (English)

1 reference

10 August 2017

1 reference

Venuja Sriretnakumar

1

1 reference

10 August 2017

Eric Huang

series ordinal

2

1 reference

10 August 2017

Daniel J Müller

series ordinal

3

1 reference

10 August 2017

language of work or name

English

0 references

publication date

12 September 2015

1 reference

Expert Opinion on Drug Metabolism & Toxicology

10 August 2017

1 reference

10 August 2017

11

1 reference

10 August 2017

11

1 reference

10 August 2017

1709-1731

1 reference

Schizophrenia: a concise overview of incidence, prevalence, and mortality

10 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Increased use of antibiotics in patients treated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recogn

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Pharmacogenetics in schizophrenia: a review of clozapine studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

The pharmacogenetics of antipsychotic-induced adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

CYP1A2 polymorphism -1545C > T (rs2470890) is associated with increased side effects to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

The CYP1A2 -163C>A polymorphism is associated with clozapine-induced generalized tonic-clonic seizures in Brazilian schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Association between CYP1A2 gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

COMT Val158Met and 5-HT1A-R -1019 C/G polymorphisms: effects on the negative symptom response to clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: replication and exploration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Investigation of melanocortin system gene variants in antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Association study of GABAA α2 receptor subunit gene variants in antipsychotic-associated weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Protein kinase cAMP-dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic-induced weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Fat mass- and obesity-associated (FTO) gene and antipsychotic-induced weight gain: an association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Genetic variants of microsomal triglyceride transfer protein (MTTP) are associated with metabolic syndrome in schizophrenic patients treated with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Association study of Val66Met polymorphism in brain-derived neurotrophic factor gene with clozapine-induced metabolic syndrome: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Effects of olanzapine on brain-derived neurotrophic factor gene promoter activity in SH-SY5Y neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Dendritic trafficking of BDNF mRNA is mediated by translin and blocked by the G196A (Val66Met) mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

The role of genetic variation across IL-1β, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Polymorphisms of the leptin and HTR2C genes and clozapine-induced weight change and baseline BMI in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

No gene is an island: the flip-flop phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Clozapine treatment causes oxidation of proteins involved in energy metabolism in lymphoblastoid cells: a possible mechanism for antipsychotic-induced metabolic alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Genetics and beyond--the transcriptome of human monocytes and disease susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Translocator protein (18 kDa)/peripheral benzodiazepine receptor specific ligands induce microglia functions consistent with an activated state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Mitochondrial disease in mouse results in increased oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

INSIG1 influences obesity-related hypertriglyceridemia in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Priorities and standards in pharmacogenetic research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Medication adherence: a review of the literature and implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

21 January 2018

Refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Animal model for schizophrenia that reflects gene-environment interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Candidate Gene Analysis Identifies a Polymorphism inHLA-DQB1Associated With Clozapine-Induced Agranulocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

CYP1A2*1F Polymorphism Decreases Clinical Response to Clozapine in Patients with Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075003

10.1517/17425255.2015.1075003

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference